Gilead Sciences (GILD): Price Target and June Short Interest Disclosure

Gilead Sciences (GILD) : 14 investment research analysts covering Gilead Sciences (GILD) have an average price target of $115.79 for the near short term. The highest target price given by the Brokerage Firm to the stock is $135 and the lowest target is $97 for the short term. Analysts expect the variance to be within $11.6 of the average price.

Gilead Sciences (GILD) reported a drop of 10.1% or 2,487,282 shares in its short interest. The short figure came in at 1.7% of the total floats. The average daily volume of 10,248,721 shares suggests that the days to cover 22,212,613 short positions, as on June 30,2016, will be 2. On June 15,2016, the short interest was 24,699,895 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Gabelli & Co initiates coverage on Gilead Sciences (NASDAQ:GILD) The brokerage firm has issued a Buy rating on the shares. The rating by the firm was issued on June 1, 2016.


Gilead Sciences (NASDAQ:GILD): On Thursdays trading session , Opening price of the stock was $86.43 with an intraday high of $86.51. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $85.27. However, the stock managed to close at $85.54, a loss of 0.24% for the day. On the previous day, the stock had closed at $85.75. The total traded volume of the day was 8,104,351 shares.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.